JUNIPER PHARMACEUTICALS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-11-07: Form 8-K; Period of report 2017-11-02; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-11-02: Form 8-K; Period of report 2017-11-02; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-09-19: Form 8-K; Period of report 2017-09-14; Description 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 2.05.
- 2017-09-11: Form 8-K; Period of report 2017-09-07; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-11-07 | 8-K | 2017-11-02 | 2.02 Results of Operations and Financial Condition | 2.02 On November 2, 2017, Juniper Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results for the three-month period ended September 30, 2017, entitled “Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results” (the “Press Release”). | d271657d8k.htm |
| 2017-11-02 | 8-K | 2017-11-02 | 2.02 Results of Operations and Financial Condition | 2.02 On November 2, 2017, Juniper Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results for the three-month period ended September 30, 2017, entitled “Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results” (the “Press Release”). | d271657d8k.htm |
| 2017-09-19 | 8-K | 2017-09-14 | 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 2.05 On September 14, 2017, the Compensation Committee of the Board of Directors (the “Board”) of Juniper Pharmaceuticals, Inc. (the “Company”) approved a reduction of its workforce by approximately 8%, primarily in the areas of new product R&D, as part of a strategic reprioritization. 5.02 As part of the strategic reprioritization and reduction in force described elsewhere in the Current Report, Bridget Martell, M.D., Chief Medical Officer, is leaving the Company. 8.01 On September 18, 2017, the Company issued a press release announcing the Company’s strategic reprioritization and reduction in force, and the departure of Dr. Martell as discussed in Item 5.02(b) above. | d455362d8k.htm |
| 2017-09-11 | 8-K | 2017-09-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 7, 2017, the Board of Directors accepted Frank Armstrong’s resignation from the Board, effective September 28, 2017. | d411060d8k.htm |
| 2017-08-03 | 8-K | 2017-08-03 | 2.02 Results of Operations and Financial Condition | 2.02 On August 3, 2017, Juniper Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results for the three-month period ended June 30, 2017, entitled “Juniper Pharmaceuticals Reports Second Quarter 2017 Financial and Operating Results” (the “Press Release”). | d435710d8k.htm |
| 2017-07-05 | 8-K | 2017-06-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 The information set forth in Item 5.07 of this Current Report on Form 8-K is incorporated by reference in this Item 5.02. 5.07 The Annual Meeting of the Stockholders was held on June 30, 2017 (“Annual Meeting”). | d408128d8k.htm |
| 2017-05-04 | 8-K | 2017-05-03 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On May 4, 2017, Juniper Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results for the three-month period ended March 31, 2017, entitled “Juniper Pharmaceuticals Reports First Quarter 2017 Financial and Operating Results” (the “Press Release”). 5.02 On May 3, 2017, Frank C. Condella, Jr. notified the Board of Directors (“Board”) of Juniper Pharmaceuticals, Inc. (the “Company”) that he will not stand for re-election when his current term expires at the Company’s 2017 Annual Meeting of Stockholders. | d382007d8k.htm |
| 2017-03-07 | 8-K | 2017-03-07 | 2.02 Results of Operations and Financial Condition | 2.02 On March 7, 2017, Juniper Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results for the three-month and twelve-month periods ended December 31, 2016, entitled “Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results” (the “Press Release”). | d350305d8k.htm |